Table 2

Demographic data of the included patients with ALS in substudy 2

Characterisation of the ALS group (n: 96)	n	%
Inclusion site
Glostrup Hospital	9	9
Bispebjerg Hospital	33	34
Roskilde Hospital	33	34
Odense Hospital	16	17
Aarhus Hospital	5	5
Age (median age: 67)
<40	3	3
40–49	12	13
50–59	13	14
60–69	28	29
>70	40	42
Age when first symptoms occurred (median age: 65)
<40	4	4
40–49	13	14
50–59	15	16
60–69	35	36
>70	29	30
Gender
Female	40	42
Male	56	58
ALS subtype I
Familial ALS	2	2
Sporadic ALS	94	98
ALS subtype II
Spinal ALS	60	63
Bulbar ALS	28	29
Both spinal and bulbar ALS	6	6
Truncal ALS	2	2
ALSFRS-R score on date collection day (median score: 37):
Mild ALS symptoms (ALSFRS-R score >36)	49	51
Moderate ALS symptoms (24< ALSFRS R score ≤36)	33	34
Severe ALS symptoms (ALSFRS-R score ≤24)	14	15
Progression rate estimation (Δtime*ALSFRS-R score on data collection day)
Slow progression rate	26	27
Medium progression rate	37	39
Aggressive progressive rate	33	34
Overall survival time from onset of symptoms (Database update: 2 May 2020)
Still alive (missing data)	39	41
Short survival time (0–2 years)	22	23
Medium survival time (2–4 years)	25	26
Long survival time (4+ years)	10	10
Cognitive impairments observed
Yes	21	22
No	75	78
Riluzole treatment on data collection day
Yes	33	34
No	63	66

ALS, Amyotrophic lateral sclerosis; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised.